Though vaccine developers rapidly adopted decentralized clinical trials during the pandemic, today there is a surprisingly slow uptake of novel technologies across vaccine studies compared to other therapy areas.
There is a real human need contingent upon clinical trials meeting their targeted enrollment, retaining participants, attaining crucial milestones, and resulting in successful outcomes.
With biologics dominating headlines, one might be tempted to think that small molecule discovery is fading, or that there is little viable target and drug space left uncovered. This simply isn’t the case.
ACRP is taking steps to help our members attract people who are “on the outside looking in”: reducing and removing barriers to entry-level employment and cheerleading for wider acknowledgment of clinical research as a true profession.
As the majority of cancers do not have known screening markers, new research is needed to be sure potential biomarkers are predictive of disease, reduce mortality, do not lead to unnecessary procedures or needless worry, and are cost-effective.